Table 3.

Crude incidence rates and risk of ASCVD in patients with RA by unprovoked VTE

	Events/patients	%	Patient-years	Incidence rate (95% CI)*	Unadjusted HR (95% CI)	Adjusted HR for age, sex and year (95% CI)	Adjusted HR (95% CI)†
Patients without prior VTE or ASCVD	1283/25 070	5.1	147 735	8.68 (8.22 to 9.17)	–	–	–
Patients with first unprovoked VTE (no prior ASCVD or VTE)	38/506	7.5	16 152	23.53 (17.12 to 32.33)	2.50 (1.81 to 3.44)	2.32 (1.69 to 3.11)	2.05 (1.43 to 2.95)
Deep venous thrombosis	21/325	6.5	11 150	18.83 (12.28 to 28.87)	2.03 (1.32 to 3.12)	2.00 (1.39 to 3.09)	1.93 (1.22 to 3.06)
Pulmonary emboli	17/181	9.4	5002	33.99 (21.13 to 54.67)	3.78 (2.50 to 5.70)	2.98 (1.92 to 4.89)	2.52 (1.57 to 4.04)

*Per 1000 patient-years.

†Adjusted for age; sex; disease duration; socioeconomic status (annual income, insurance and location of residency); ethnicity; smoking; hypertension; diabetes; chronic kidney disease; comorbidity index; body mass index; Health Assessment Questionnaire; patient global and pain scores; glucocorticoid use disease-modifying antirheumatic drugs (DMARDs) including methotrexate, hydroxychloroquine, tumour necrosis factor-α inhibitor (TNFi) and non-TNFi biological DMARDs (bDMARDs); non-steroidal anti-inflammatory drugs; statins; fracture; pulmonary disease; prior count of conventional synthetic DMARDs (csDMARDs) and bDMARDs; and calendar year.

ASCVD, atherosclerotic cardiovascular disease; RA, rheumatoid arthritis; VTE, venous thromboembolism.